Limits...
Poor survival is associated with the methylated degree of zinc-finger protein 545 (ZNF545) DNA promoter in gastric cancer.

Deng J, Liang H, Ying G, Dong Q, Zhang R, Yu J, Fan D, Hao X - Oncotarget (2015)

Bottom Line: Zinc-finger protein 545 (ZNF545) was identified as a gastric tumour suppressor and potentially independent prognostic factor.In the methylation-specific PCR (MSP) analysis cohort, we found that GC patients with hypermethylated ZNF545 promoter exhibited significantly shorter median OS than those with unmethylated ZNF545 promoter and those with hypomethylated ZNF545 promoter.These findings indicated that the methylated CpG sites of the ZNF545 promoter could be used for the clinical prediction of the prognosis of GC.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Tianjin Medical University Cancer Hospital, City Key Laboratory of Tianjin Cancer Center and National Clinical Research Center for Cancer, Tianjin, China.

ABSTRACT
Zinc-finger protein 545 (ZNF545) was identified as a gastric tumour suppressor and potentially independent prognostic factor. At the present study, we found that lower expression of ZNF545 was specific in gastric cancer (GC) tissues, and the inconsistently methylated levels of ZNF545 promoter were identified in the gastric cancer tissues. In the methylation-specific PCR (MSP) analysis cohort, we found that GC patients with hypermethylated ZNF545 promoter exhibited significantly shorter median OS than those with unmethylated ZNF545 promoter and those with hypomethylated ZNF545 promoter. In the other cohort, we also demonstrated that GC patients with three or more methylated CpG sites in the ZNF545 promoter were significantly associated with poor survival by using the bisulphite gene sequencing (BGS). The methylated degrees of five CpG sites (-232, -214, -176, -144 and -116) could also provide distinct survival discrimination of patients with GC. These findings indicated that the methylated CpG sites of the ZNF545 promoter could be used for the clinical prediction of the prognosis of GC.

Show MeSH

Related in: MedlinePlus

MSP detection of ZNF545 promoter methylation in different GC tissues and normal gastric mucosal tissues(Representation: T, GC tissues; N, normal gastric mucosal tissues; M0, non-methylation; M1, hypomethylation; M2, hypermethylation; U, unmethylation).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4414205&req=5

Figure 2: MSP detection of ZNF545 promoter methylation in different GC tissues and normal gastric mucosal tissues(Representation: T, GC tissues; N, normal gastric mucosal tissues; M0, non-methylation; M1, hypomethylation; M2, hypermethylation; U, unmethylation).

Mentions: We conducted MSP analysis and detected the different degrees of methylation (including hypermethylation, hypomethylation and non-methylation) of the ZNF545 promoter in 300 GC tissues; by contrast, the ZNF545 promoter was not methylated in the 25 normal gastric mucosal tissues (Figure 2). Among the 300 GC tissues, 72 (24%) presented hypermethylated ZNF545 promoter, 61 (20.33%) revealed hypomethylated ZNF545 promoter and 167 (55.67%) presented with unmethylated ZNF545 promoter.


Poor survival is associated with the methylated degree of zinc-finger protein 545 (ZNF545) DNA promoter in gastric cancer.

Deng J, Liang H, Ying G, Dong Q, Zhang R, Yu J, Fan D, Hao X - Oncotarget (2015)

MSP detection of ZNF545 promoter methylation in different GC tissues and normal gastric mucosal tissues(Representation: T, GC tissues; N, normal gastric mucosal tissues; M0, non-methylation; M1, hypomethylation; M2, hypermethylation; U, unmethylation).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4414205&req=5

Figure 2: MSP detection of ZNF545 promoter methylation in different GC tissues and normal gastric mucosal tissues(Representation: T, GC tissues; N, normal gastric mucosal tissues; M0, non-methylation; M1, hypomethylation; M2, hypermethylation; U, unmethylation).
Mentions: We conducted MSP analysis and detected the different degrees of methylation (including hypermethylation, hypomethylation and non-methylation) of the ZNF545 promoter in 300 GC tissues; by contrast, the ZNF545 promoter was not methylated in the 25 normal gastric mucosal tissues (Figure 2). Among the 300 GC tissues, 72 (24%) presented hypermethylated ZNF545 promoter, 61 (20.33%) revealed hypomethylated ZNF545 promoter and 167 (55.67%) presented with unmethylated ZNF545 promoter.

Bottom Line: Zinc-finger protein 545 (ZNF545) was identified as a gastric tumour suppressor and potentially independent prognostic factor.In the methylation-specific PCR (MSP) analysis cohort, we found that GC patients with hypermethylated ZNF545 promoter exhibited significantly shorter median OS than those with unmethylated ZNF545 promoter and those with hypomethylated ZNF545 promoter.These findings indicated that the methylated CpG sites of the ZNF545 promoter could be used for the clinical prediction of the prognosis of GC.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Tianjin Medical University Cancer Hospital, City Key Laboratory of Tianjin Cancer Center and National Clinical Research Center for Cancer, Tianjin, China.

ABSTRACT
Zinc-finger protein 545 (ZNF545) was identified as a gastric tumour suppressor and potentially independent prognostic factor. At the present study, we found that lower expression of ZNF545 was specific in gastric cancer (GC) tissues, and the inconsistently methylated levels of ZNF545 promoter were identified in the gastric cancer tissues. In the methylation-specific PCR (MSP) analysis cohort, we found that GC patients with hypermethylated ZNF545 promoter exhibited significantly shorter median OS than those with unmethylated ZNF545 promoter and those with hypomethylated ZNF545 promoter. In the other cohort, we also demonstrated that GC patients with three or more methylated CpG sites in the ZNF545 promoter were significantly associated with poor survival by using the bisulphite gene sequencing (BGS). The methylated degrees of five CpG sites (-232, -214, -176, -144 and -116) could also provide distinct survival discrimination of patients with GC. These findings indicated that the methylated CpG sites of the ZNF545 promoter could be used for the clinical prediction of the prognosis of GC.

Show MeSH
Related in: MedlinePlus